Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 8, 2012, Pages 917-923

  Beales, Ian L P ^a,b   Vardi, Inna ^a   Dearman, Leanne ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

aspirin; Barrett's oesophagus; oesophageal cancer; statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED;

EID: 84864031678     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283543f01     Document Type: Article

References (53)

1. Botterweck AA, Schouten LJ, Volovics A, Dorant E, Van den Brandt PA. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29:645-654.
2. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100:1184-1187.
3. Wu X, Chen VW, Andrews PA, Ruiz B, Correa P. Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non- Hispanic blacks in the United States: Subsite and histology differences. Cancer Causes Control 2007; 18:585-593.
4. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001; 92:549-555.
5. Sikkema M, De Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: A systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8:235-244.
6. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am J Epidemiol 2008; 168:237-249.
7. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011; 141:460-468.
8. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: A population-based study with temporal trends. Am J Gastroenterol 1990; 104:1356-1362.
9. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365:1375-1383.
10. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140:e18-e52.
11. Chow WH, Finkle WD, Mclaughlin JK, Frankl H, Ziel HK, Fraumeni JF Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274:474-477.
12. Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000; 11:231-238.
13. Cooper BT, ChapmanW, Neumann CS, Gearty JC. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: Observations on regression and cancer incidence. Aliment Pharmacol Ther 2006; 23:727-733.
14. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7:1299-1304.
15. Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: A nested case- control study in the UK. Gut 2006; 55:1538-1544.
16. Souza RF, Shewmake K, Beer DG, Cryer B, Spechler SJ. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000; 60:5767-5772.
17. Vona-Davis L, Riggs DR, Jackson BJ, Mcfadden DW. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1). J Surg Res 2004; 119:143-148.
18. Oyama K, Fujimura T, Ninomiya I, Miyashita T, Kinami S, Fushida S, et al. A COX-2 inhibitor prevents the esophageal inflammation-metaplasiaadenocarcinoma sequence in rats. Carcinogenesis 2005; 26:565-570.
19. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: An in vitro study. J Natl Cancer Inst 2002; 94:422-429.
20. Buttar NS,Wang KK, Leontovich O,Westcott JY, Pacifico RJ, Anderson MA, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 2002; 122:1101-1112.
21. Corley DA, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and metaanalysis. Gastroenterology 2003; 124:47-56.
22. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: Results from a cohort study and a metaanalysis. Br J Cancer 2009; 100:551-557.
23. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: A prospective study. Lancet Oncol 2005; 6: 945-952.
24. Beales IL, Ogunwobi OO. Microsomal prostaglandin E synthase-1 inhibition blocks proliferation and enhances apoptosis in oesophageal adenocarcinoma cells without affecting endothelial prostacyclin production. Int J Cancer 2010; 126:2247-2255.
25. Solomon SD, Mcmurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080.
26. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136:161-172.
27. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
28. Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res 2009; 181:161-169.
29. Van der Burgh A, Dees J, Hop WC, Van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39:5-8.
30. Solaymani-Dodaran M, Logan RF, West J, Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study. Am J Gastroenterol 2005; 100: 2616-2621.
31. Moayyedi P, Burch N, Akhtar-Danesh N, Enaganti SK, Harrison R, Talley NJ, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008; 27:316-320.
32. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology 2011; 140:1084-1091.
33. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771-777.
34. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 19:CD004816.
35. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: A network metaanalysis of 170 255 patients from 76 randomized trials. QJM 2011; 104:109-124.
36. Ogunwobi OO, Beales IL. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells. Am J Gastroenterol 2008; 103:825-837.
37. Holstein SA, Wohlford-Lenane CL, Wiemer DF, Hohl RJ. Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins. Biochemistry 2003; 42:4384-4391.
38. Vaklavas C, Chatzizisis YS, Tsimberidou AM. Common cardiovascular medications in cancer therapeutics. Pharmacol Ther 2011; 130:177-190.
39. Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90:635-637.
40. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening statins for possible carcinogenic risk: Up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008; 17:27-36.
41. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: Population based cohort study using the QResearch database. BMJ 2010; 340:c2197.
42. Bhutta HY, Clark A, Holt S, Lewis MP, Hart AR. Oesophageal cancer-an aetiological investigation into the potential protective effect of statins in the UK general practice research database (GPRD) [Abstract]. Gut 2011; 60 (Suppl 1):A36-A37.
43. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010; 138:2260-2266.
44. Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 2011; 141:2000-2008.
45. Kantor ED, Onstad L, Blount PL, Reid BJ, Vaughan TL. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2012; 21:456-461.
46. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85:1457-1459.
47. Watson A, Heading RC, Shepherd NA. Guidelines for the diagnosis and management of Barrett's columnar-lined oesophagus. London: BRITISH Society of Gastroenterology; 2005.
48. Morgan C, Lunt M, Bunn D, Scott DG, Symmons DP. Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology (Oxford) 2007; 46:1819-1823.
49. Broughton T, Sington J, Beales I. Statin use is associated with a reduced incidence of colorectal adenomatous polyps: A case-control study. Gut 2011; 60 (Suppl 1):A5.
50. Konturek PC, Burnat G, Hahn EG. Inhibition of Barrett's adenocarcinoma cell growth by simvastatin: Involvement of COX-2 and apoptosis-related proteins. J Physiol Pharmacol 2007; 58 (Suppl 3):141-148.
51. Lee JE, Baba Y, Ng K, Giovannucci E, Fuchs C, Ogino S, et al. Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 2011; 4:1808-1815.
52. Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH. Review article: The potential of combinational regimen with non-steroidal antiinflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2005; 21:321-329.
53. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: Surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am 2006; 15:751-764.